MannKind Corporation
MNKDHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. The company carries a $1.31B market cap, placing it firmly in the small-cap category. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Market Cap
$1.31B
Beta
1.10
P/E (TTM)
—
P/E (Fwd)
31.84
EPS (TTM)
$-0.15
EPS (Fwd)
$0.13
ROE
—
ROA
0.8%
Cash
$111.1M
Total Debt
$433.8M
Free CF
$40.3M
52W Change
-26.3%
Annual Financials
Cash vs Debt
Where MNKD stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, MNKD finished 7.57% above its 150-day moving average ($3.70) and 4.56% below its 200-day moving average ($4.17). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MNKD overbought or oversold?
At the September 2, 2026 close, MNKD's RSI(14) was 54.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $111.1M in cash, though total debt stands at $433.8M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $40.3M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROA of 0.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $99.8M (2022) to $349.0M (2025), reflecting a 250% increase over the period.
Investors considering MannKind Corporation should weigh the typical risks associated with MNKD's sector, size, and financial profile against their own risk tolerance and investment objectives. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence MannKind Corporation's trajectory.